Home
/
Lexeo Therapeutics, Inc.
/
Financials
/
Quarterly
Lexeo Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Lexeo Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2023
Sep 30, 2022
$531.0K
Dec 11, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($20.28M)
Nov 5, 2025
Q3
2025
Jun 30, 2025
($26.10M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($26.10M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($32.66M)
May 12, 2025
Q2
2025
Mar 31, 2025
($32.66M)
Aug 14, 2025
Q3
2025
Mar 31, 2025
($32.66M)
Nov 5, 2025
Q3
2025
Dec 31, 2024
($98.30M)
Nov 5, 2025
Q1
2025
Dec 31, 2024
($98.30M)
May 12, 2025
Q2
2025
Dec 31, 2024
($98.30M)
Aug 14, 2025
Q3
2025
Sep 30, 2024
($29.49M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($21.24M)
Aug 14, 2025
Q3
2025
Jun 30, 2024
($21.24M)
Nov 5, 2025
Q2
2025
Mar 31, 2024
($21.68M)
Aug 14, 2025
Q3
2025
Mar 31, 2024
($21.68M)
Nov 5, 2025
Q1
2025
Mar 31, 2024
($21.68M)
May 12, 2025
Q1
2024
Dec 31, 2023
($66.40M)
May 9, 2024
Q2
2024
Dec 31, 2023
($66.40M)
Aug 12, 2024
Q3
2024
Dec 31, 2023
($66.40M)
Nov 13, 2024
Q3
2024
Sep 30, 2023
($20.11M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($13.44M)
Aug 12, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($21.65M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($30.69M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($33.81M)
May 12, 2025
Q3
2025
Sep 30, 2024
($31.54M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($23.55M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($23.29M)
May 12, 2025
Q3
2024
Sep 30, 2023
($20.27M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($13.98M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($19.29M)
May 9, 2024
Q3
2023
Sep 30, 2022
($17.48M)
Dec 11, 2023